temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m),
(1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).
5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:
25 hours
6. List with description of all entities that may be affected by the proposed rule:
Pharmacists, prescribers, courts, police and the Controlled Substances Board
7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:
On September 11, 2015, the United States Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register removing [123I]ioflupane from schedule II of the federal Controlled Substances Act. The scheduling action was effective September 11, 2015.
8. Anticipated economic impact of implementing the rule (note if the rule is likely to have a significant economic impact on small businesses):
None to minimal. It is not likely to have a significant economic impact on small businesses.
Contact Person: Sharon Henes, Administrative Rules Coordinator, (608) 261-2377
Chair
Date Submitted
